

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (canceled).

Claim 2 (currently amended): The method according to claim ~~± 27~~, wherein the donor cells ~~(6)~~ contain naturally occurring stem cells.

Claim 3 (currently amended): The method according to claim ~~± 27~~, wherein the cells ~~(2)~~ of the morula ~~(7)~~ or the internal cell mass ~~(4)~~ of the blastocyst ~~(1)~~ are prepared in a culture dish ~~(8, 9, 10)~~ or are used to prepare a soluble matrix fraction.

Claim 4 (currently amended): The method according to claim ~~± 27~~, wherein the donor cells ~~(6)~~ are obtained from umbilical cord blood.

Claim 5 (currently amended): The method according to claim ~~± 27~~, wherein the donor cells ~~(6)~~ are obtained from placenta.

Claim 6 (currently amended): The method according to claim ±
27, wherein the donor cells ~~(6)~~ are obtained from bone marrow.

Claim 7 (currently amended): The method according to claim ±
27, wherein the donor cells ~~(6)~~ are obtained from fatty tissue.

Claim 8 (currently amended): The method according to claim ±
27, wherein the cells ~~(2)~~ of the morula ~~(7)~~ or the internal cell
mass ~~(4)~~ of the blastocyst ~~(1)~~ are tetraploid cells.

Claim 9 (currently amended): The method according to claim ±
27, wherein the cells ~~(2)~~ of the morula ~~(7)~~ or the internal cell
mass ~~(4)~~ of the blastocyst ~~(1)~~ has cells whose genome contains
vectors that cause a lethal sensitivity to appropriate
cultivation conditions in comparison to the ~~particular~~
corresponding wild type.

Claim 10 (currently amended): The method according to claim
± 27, wherein the genome of the donor cells ~~(6)~~ contains a vector
which causes a resistance to additives of culture media.

Claim 11 (currently amended): The method according to claim
± 27, wherein the survivability of the cells ~~(2)~~ of the morula

~~(7)~~ or the internal cell mass ~~(4)~~ of the blastocyst ~~(1)~~ is reduced by adding ~~suitable~~ selected antibodies.

Claim 12 (currently amended): The method according to claim 9, wherein the survivability of the cells ~~(2)~~ of the morula ~~(7)~~ or the cells of the internal cell mass ~~(4)~~ of the blastocyst ~~(1)~~ is reduced in a way that is tailored to the varying degrees of differentiation of the donor cells ~~(6)~~ and is chronologically well-ordered.

Claim 13 (currently amended): The method according to claim ~~± 27~~, wherein before the donor cells ~~(6)~~ are supplied into the morula ~~(7)~~ or the blastocyst ~~(1)~~, the donor cells ~~(6)~~ are brought into contact in culture dishes with other blastocysts or internal cell masses isolated from other blastocysts, and those donor cells having a relatively high contact affinity are isolated and supplied to the morula ~~(7)~~ and/or blastocyst ~~(1)~~ first cited.

Claim 14 (currently amended): The method according to claim ~~± 27~~, wherein before the donor cells ~~(6)~~ are supplied into the morula ~~(7)~~ or the blastocyst ~~(1)~~, the donor cells ~~(6)~~ are equipped with a genetic marker that ensures cells having a lower degree of differentiation are isolated and supplied into the morula ~~(7)~~ or blastocyst ~~(1)~~.

Claim 15 (currently amended): The method according to claim ~~± 27~~, wherein the morula ~~(7)~~ or blastocyst ~~(1)~~ is a mouse morula or mouse blastocyst.

Claim 16 (currently amended): The method according to claim ~~± 27~~, wherein the morula ~~(7)~~ or blastocyst ~~(1)~~ is a pig morula or pig blastocyst.

Claim 17 (currently amended): The method according to claim ~~± 27~~, wherein when the donor cells ~~(6)~~ are supplied to a blastocyst ~~(1)~~, the supply is performed through injection.

Claim 18 (currently amended): The method according to claim ~~± 27~~, wherein when the donor cells ~~(6)~~ are supplied to a morula ~~(7)~~, the supply is performed through aggregation.

Claim 19 (currently amended): The method according to claim ~~± 27~~, wherein the donor cells ~~(6)~~ are human donor cells.

Claims 20-22 (canceled).

Claim 23 (currently amended): The method according to claim ~~±~~ 27, wherein the donor cells ~~(6)~~ are donor cells of non-human mammals.

Claims 24-26 (canceled).

Claim 27 (new): A method for producing cell lines or individual organs comprising the steps of:

(a) cultivating a nonhuman morula or a nonhuman blastocyst under conditions that enable a further development of the morula or blastocyst to occur in stages in which newly formed cell lines having a high degree of differentiation are produced;

(b) supplying differentiable donor cells to the morula or the blastocyst to produce cell lines; and

(c) isolating the cell lines or further differentiating the cell lines into organs through transfer of the blastocyst into a surrogate mother animal;

wherein the cells of the morula or an internal cell mass of the blastocyst have a restricted survivability in comparison to a corresponding wild type or survivability of the cells or the internal cell mass is reduced through selected cultivation conditions; and

wherein the donor cells supplied to the morula or blastocyst have varying degrees of differentiation and are of non-embryonic origin.

ELECTION OF INVENTION:

The Patent Examiner has made new grounds of restriction and requires the selection of one of the following groups of invention for further prosecution:

Group I: Claims 1-19 and 23 (claims 1-4, 8-14, 16, 17 and 19, drawn to elected species), drawn to a method for producing cell lines; or

Group II: Claims 1-19 and 23 (claims 1-4, 8-14, 16, 17 and 19, drawn to elected species), drawn to a method for producing individual organs.

ELECTION:

Applicants respectfully elect, with traverse, the invention of Group I, claims 27 (claim 1 having been canceled), 2-19 and 23, for further prosecution.